Please login to the form below

Not currently logged in
Email:
Password:

Rixathon/Riximyo

This page shows the latest Rixathon/Riximyo news and features for those working in and with pharma, biotech and healthcare.

Sandoz joins Europe's MabThera biosimilar push

Sandoz joins Europe's MabThera biosimilar push

Sandoz will sell its biosimilar under the Rixathon/Riximyo brand names, and the firm's biopharma head, Carol Lynch, said the approval is "a big win for patients in Europe with ... There is no word on pricing for Rixathon just yet, but biosimilars

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics